Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$5.2B
283M shares
52-week range
$14.19 – $42.50
13% from low
Sector
SERVICES-MEDICAL LABORATORIES
Exchange
NASDAQ
CS
Borrow rate
0.77%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2017 | 2018 | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $348.4M | $432.1M | $416.5M | $294.0M | $258.5M | $306.1M | $412.3M | $812.0M |
| Cost of revenue | $179.1M | $218.5M | $216.0M | $109.9M | $178.5M | $216.8M | $233.5M | $272.9M |
| Gross profit | $169.3M | $213.6M | $200.5M | $184.2M | $80.0M | $89.3M | $178.8M | $539.2M |
| Gross margin | 48.6% | 49.4% | 48.1% | 62.6% | 31.0% | 29.2% | 43.4% | 66.4% |
| R&D | $0 | $0 | $0 | $0 | $101.3M | $116.9M | $113.9M | $45.3M |
| Operating income | $105.7M | $148.8M | $130.3M | $139.1M | −$315.8M | −$319.6M | −$257.1M | $45.1M |
| EBITDA | $223.5M | $283.3M | $248.3M | $254.5M | −$245.9M | −$260.8M | −$183.0M | $11.4M |
| Net income | $72.1M | $78.6M | $31.0M | $27.7M | −$320.8M | −$341.4M | −$281.9M | −$538.0M |
| Net margin | 20.7% | 18.2% | 7.4% | 9.4% | -124.1% | -111.5% | -68.4% | -66.2% |
| EPS (diluted) | 3.68 | 3.97 | 1.72 | 1.55 | -1.57 | -1.82 | -2.70 | -1.90 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.0B | $0.13 | $0.13–$0.13 | 8 |
| 2027 | $1.2B | $0.33 | $0.18–$0.49 | 8 |
| 2028 | $1.4B | $0.55 | $0.38–$0.90 | 7 |
| 2029 | $1.6B | $0.78 | $0.74–$0.81 | 2 |
Forward consensus · source: Financial Modeling Prep
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
www.carislifesciences.comNo one on the platform currently holds CAI.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 449,900 | $8.0M |
No one on the platform has traded CAI yet.
| $9.3B |
| — |
| JAZZJazz Pharmaceuticals plc | $241.70 | +1.67% | $15.2B | — |
| MDGLMadrigal Pharmaceuticals, Inc. | $542.02 | +2.80% | $12.5B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$CAI people are literally blind… not even 1k watching this yet
View on StockTwits ↗$CAI Caris Assure is a single blood draw built to catch cancer early, and in their study it flagged 83 to 96% across stages 1 to 4 with a 0.4% false positive rate. And detection is only one piece of it. The same platform also helps pick the treatment and then watches for the cancer coming back, and every test it runs feeds the data that makes the next one smarter. No one else has the whole stack on one platform
View on StockTwits ↗$CAI Druckenmiller avg in the 17s plus 100m buybacks $QQQ $DIA $SPY ai biotech will be the next sector to boom
View on StockTwits ↗$CAI and $TEM are essentially targeting the same massive market, with just two main distinctions: $TEM is operating at a much larger scale, while $CAI prioritizes analytical depth over breadth and is already bringing in consistent cash flow. Don't let the current market caps fool you. This is a multi-trillion-dollar race to become the dominant Biology Ontology platform in the industry.
View on StockTwits ↗$CAI insider bought a lot recently also and now we got company authorizing $100M stock buyback...they are screaming that these prices are way below its true potential. Cash and proftiability to back it up.
View on StockTwits ↗$CAI Somebody’s holding this one down. Probably for accumulation. I bet it won’t stay in the $16 s long .
View on StockTwits ↗$CAI 08:35 on Jun. 08 2026 Caris Life Sciences Announces $100M Buyback Plan #tradeideas
View on StockTwits ↗$CAI Now we are talking, finally the attention it deserves. Price target 30$
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.